Using a Rumen Protected Lysine (RPL) product in dairy cow diets to increase production, improve efficiency, or reduce crude protein levels requires confidence in the bioavailability value for that product.
Bioavailability measures the efficacy of a product. In simple terms, it is how many grams of MP lysine the product provides for the cow to utilize.
Multiple methods have been developed to evaluate bioavailability. In general, methods can be classified as in vitro, in situ or in vivo, and all vary in complexity, expense and labor involved.
Overall, in vitro and in vivo techniques are favored when a quick and inexpensive approximation is needed, but are removed from what’s going on with the animal. On the other hand, in vivo techniques, such as the dose-response method, measure the appearance of lysine in the blood of the animal as the result of feeding RPL. This technique is currently the most accurate option as it accounts for animal effects such the mechanics of ingestion, rumination, and rate of passage through the rumen.
USA Lysine®’s bioavailability values have been evaluated by two plasma free lysine dose response studies. They were conducted at two separate research facilities approximately six years apart. Each study validated USA Lysine’s published bioavailability values. The results indicate that 100 grams of USA Lysine provide 44 grams of MP lysine. This is over 2x the amount of any other RPL product available in the market.
Please download and read the two USA Lysine bioavailability studies below to learn more.
Kemin invested a tremendous amount of resources to bring a true next generation product onto the market. To evaluate whether the competition has made statistically significant improvements with their product line, review the abstracts below.
Abstract M257 can be found on page 10 of the document.
Abstract T212 can be found on page 7 of the document.